MedTrace Logo

Ultrasound Beams as an Adjunct to Reperfusion Therapy in STEMI

NCT02299609 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-11-24

No results posted yet for this study

Summary

Successfully perfused STEMI patients will receive routine transthoracic echocardiography qid for 4 days or placebo. Myocardial function and infarct size will be evaluated at 3 and 6 months.

Conditions

Interventions

OTHER

Ultrasound beams Philips HD11 XE®

Ultrasound beams used during standard echocardiography

Sponsors & Collaborators

  • Sakarya University

    lead OTHER

Principal Investigators

  • Ramazan Akdemir, MD · Sakarya University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-12-31
Completion
2016-02-29

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02299609 on ClinicalTrials.gov